顺铂和奈达铂的临床应用

摘要/Abstract

摘要：多年的临床研究表明顺铂和奈达铂对大部分实体瘤如头颈部肿瘤、食管癌、肺癌、膀胱癌、卵巢上皮癌、睾丸癌和宫颈癌等有效，并且奈达铂在亚洲地区常常作为顺铂的替代药，但来自Ⅲ期临床试验的证据并不充足，临床医生在使用奈达铂替代顺铂治疗时应谨慎。

乔云锋，李萍，付振明. 顺铂和奈达铂的临床应用[J]. 国际肿瘤学杂志, 2018, 45(8): 561-565.

Qiao Yunfeng, Li Ping, Fu Zhenming. Clinical application of cisplatin and nedaplatin[J]. Journal of International Oncology, 2018, 45(8): 561-565.

［1］ Rosenberg B, Van Camp L, Grimley EB, et al. The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum (Ⅳ) complexes［J］. J Biol Chem, 1967, 242(6): 13471352. ［2］ Uehara T, Watanabe H, Itoh F, et al. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats［J］. Arch Toxicol, 2005, 79(8): 451460. DOI: 10.1007/s0020400506486. ［3］ Goto T, Takano M, Ohishi R, et al. Single nedaplatin treatment as salvage chemotherapy for platinum/taxaneresistant/refractory epithelial ovarian, tubal and peritoneal cancers［J］. J Obstet Gynaecol Res, 2010, 36(4): 764768. DOI: 10.1111/j.14470756.2010.01217.x. ［4］ Wee JT, Ha TC, Loong SL, et al. Is nasopharyngeal cancer really a "Cantonese cancer"?［J］. Chin J Cancer, 2010, 29(5): 517526. ［5］陈骏, 王文华, 顾健. 奈达铂与顺铂治疗晚期鼻咽癌的有效性和安全性系统分析［J］. 中国药学杂志, 2016, 51(2): 144150. DOI: 10.11669/cpj.2016.02.016. ［6］ Tang C, Wu F, Wang R, et al. Comparison between nedaplatin and cisplatin plus docetaxel combined with intensitymodulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized phase Ⅱ clinical trial［J］. Am J Cancer Res, 2016, 6(9): 20642075. ［7］ Tang LQ, Chen DP, Guo L, et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage ⅡⅣB nasopharyngeal carcinoma: an openlabel, noninferiority, randomised phase 3 trial［J］. Lancet Oncol, 2018, 19(4): 461473. DOI: 10.1016/S14702045(18)301049. ［8］ Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008［J］. Int J Cancer, 2010, 127(12): 28932917. DOI: 10.1002/ijc.25516. ［9］ Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013［J］. CA Cancer J Clin, 2013, 63(1): 1130. DOI: 10.3322/caac.21166. ［10］ Ettinger DS, Akerley W, Borqhaei H, et al. Nonsmall cell lung cancer, version 2.2013［J］. J Natl Compr Canc Netw, 2013, 11(6): 645653; quiz 653. DOI: 10.6004/jnccn.2013.0084. ［11］ Suehisa H, Toyooka S. Adjuvant chemotherapy for completely resected nonsmallcell lung cancer［J］. Acta Medica Okayama, 2009, 63(5): 223230. DOI: 10.18926/AMO/31842. ［12］ Li CH, Liu MY, Liu W, et al. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced nonsmall cell lung cancer［J］. Asian Pac J Cancer Prev, 2014, 15(2): 731736. DOI: 10.7314/APJCP.2014.15.2.731. ［13］ Mitani A, Jo T, Yasunaga H, et al. Venous thromboembolic events in patients with lung cancer treated with cisplatinbased versus carboplatin/nedaplatinbased chemotherapy［J］. Anticancer Drugs, 2018, 29(6): 560564. DOI: 10.1097/CAD.0000000000000625. ［14］ Haddad TC, Greeno EW. Chemotherapyinduced thrombosis［J］. Thromb Res, 2006, 118(5): 555568. DOI: 10.1016/j.thromres.2005.10.015. ［15］ Liu Y, Yu S, Liu S, et al. Comparison of nedaplatinbased versus cisplatinbased chemotherapy for advanced nonsmall cell lung cancer among East Asian populations: a metaanalysis［J］. Sci Rep, 2015, 5: 10516. DOI: 10.1038/srep10516. ［16］ Shukuya T, Yamanaka T, Seto T, et al. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, openlabel, phase 3 trial［J］. Lancet Oncol, 2015, 16(16): 16301638. DOI: 10.1016/S14702045(15)003058. ［17］ Horita N, Nagashima A, Nakashima K, et al. The best platinum regimens for chemonaive incurable nonsmall cell lung cancer: network metaanalysis［J］. Sci Rep, 2017, 7(1): 13185. DOI: 10.1038/s41598017137242. ［18］ Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014［J］. CA Cancer J Clin, 2014, 64(1): 929. DOI: 10.3322/caac.21208. ［19］ Zhao P, Dai M, Chen W, et al. Cancer trends in China［J］. Jpn J Clin Oncol, 2010, 40(4): 281285. DOI: 10.1093/jjco/hyp187. ［20］ Rustgi AK, ElSerag HB. Esophageal carcinoma［J］. N Engl J Med, 2014, 371(26): 24992509. DOI: 10.1056/NEJMra1314530. ［21］ Yamashita H, Nakagawa K, Tago M, et al. Radiation therapy combined with cisdiammineglycolatoplatinum (nedaplatin) and 5fluorouracil for Japanese stage ⅡⅣ esophageal cancer compared with cisplatin plus 5fluorouracil regimen: a retrospective study［J］. Dis Esophagus, 2006, 19(1): 1519. DOI: 10.1111/j.14422050.2006.00531.x. ［22］ Fujita Y, Hiramatsu M, Kawai M, et al. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5fluorouracil: a retrospective study［J］. Dis Esophagus, 2008, 21(6): 496501. DOI: 10.1111/j.14422050.2007.00806.x. ［23］ Zhang F, Wang Y, Wang ZQ, et al. Efficacy and safety of cisplatinbased versus nedaplatinbased regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and metaanalysis［J］. Dis Esophagus, 2016, 30(2): 18. DOI: 10.1111/dote.12490. ［24］ Laack E, Andritzky B, Dürk H, et al. Docetaxel and cisplatin as firstline treatment for patients with metastatic esophageal cancer: a pilot study［J］. Onkologie, 2005, 28(12): 647650. DOI: 10.1159/000089102. ［25］ Zhang X, Shen L, Li J, et al. A phase Ⅱ trial of paclitaxel and cisplatin in patients with advanced squamouscell carcinoma of the esophagus［J］. Am J Clin Oncol, 2008, 31(1): 2933. DOI: 10.1097/COC.0b013e3181131ca9. ［26］ Jin J, Xu X, Wang F, et al. Secondline combination chemotherapy with docetaxel and nedaplatin for Cisplatinpretreated refractory metastatic/recurrent esophageal squamous cell carcinoma［J］. J Thorac Oncol, 2009, 4(8): 10171021. DOI: 10.1097/JTO.0b013e3181add9c7. ［27］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65: 87108. DOI: 10.3322/caac.21262. ［28］ Gaffney DK, EricksonWittmann BA, Jhingran A, et al. ACR appropriateness criteria on advanced cervical cancer expert panel on radiation oncologygynecology［J］. Int J Radiat Oncol Biol Phys, 2011, 81(3): 609614. DOI: 10.1016/j.ijrobp.2010.11.005. ［29］ Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions［J］. J Clin Oncol, 2007, 25(20): 29522965. DOI: 10.1200/JCO.2007.10.8324. ［30］ Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatinbased radiotherapy and chemotherapy for locally advanced cervical cancer［J］. N Engl J Med, 1999, 340(15): 11441153. DOI: 10.1056/NEJM199904153401502. ［31］ Zuliani AC, Esteves SC, Teixeira LC, et al. Concomitant cisplatin plus radiotherapy and highdoserate brachytherapy versus radiotherapy alone for stage ⅢB epidermoid cervical cancer: a randomized controlled trial［J］. J Clin Oncol, 2014, 32(6): 542547. DOI: 10.1200/JCO.2013.50.1205. ［32］ Jung HS, Erkin OC, Kwon MJ, et al. The synergistic therapeutic effect of cisplatin with human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo［J］. Int J Cancer, 2012, 130(8): 19251936. DOI: 10.1002/ijc.26197. ［33］王海红. 顺铂与奈达铂同步放化疗治疗中晚期宫颈癌的临床对比研究［J］. 中国医药指南, 2015, 13(5): 131132. DOI: 10.15912/j.cnki.gocm.2015.05.094. ［34］ Kagabu M, Shoji T, Murakami K, et al. Clinical efficacy of nedaplatinbased concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study［J］. Int J Clin Oncol, 2016, 21(4): 735740. DOI: 10.1007/s1014701609464. ［35］ Li P, Zhang R, Nie Z, et al. Comparison of nedaplatin and cisplatinbased concurrent chemoradiotherapy in locally advanced cervical cancer patients: a propensity score analysis［J］. Int J Gynecol Cancer, 2018, 28(5): 10291037. DOI: 10.1097/IGC.0000000000001265.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

Clinical application of cisplatin and nedaplatin

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价